• General
    Information
    • Welcome Message
    • Virtual Meeting Guide
    • Important Dates
  • Program
    • Program (February 17 – 20)
    • Highlights Europe & Asia
      (March 3 & 4)
    • Industry & Satellite Symposia
  • Promotion,
    Advertising & Exhibits
    • Advertising & Promotion
    • Exhibits
  • Registration
    Now Closed

  • Access the
    Recordings

    • Welcome Message
    • Virtual Meeting Guide
    • Important Dates
    • Press & Media
    • Registration
    • Promotion & Advertising
    • Exhibits
    • Call for Abstracts
    • Program (February 17 – 20)
    • Highlights Europe & Asia
      (March 3 & 4)
    • Industry & Satellite Symposia
MENU
  • Home
  • Join Mailing List
  • IASLC.org
  • Contact Us
  • General
    Information
    • Welcome Message
    • Virtual Meeting Guide
    • Important Dates
  • Program
    • Program (February 17 – 20)
    • Highlights Europe & Asia
      (March 3 & 4)
    • Industry & Satellite Symposia
  • Promotion,
    Advertising & Exhibits
    • Advertising & Promotion
    • Exhibits
  • Registration
    Now Closed

  • Access the
    Recordings

  • Home
  • Join Mailing List
  • IASLC.org
  • Contact Us
  • #TTLC21
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
Conquering Thoracic Cancers Worldwide
  • General
    Information
    • Welcome Message
    • Virtual Meeting Guide
    • Important Dates
  • Program
    • Program (February 17 – 20)
    • Highlights Europe & Asia
      (March 3 & 4)
    • Industry & Satellite Symposia
  • Promotion,
    Advertising & Exhibits
    • Advertising & Promotion
    • Exhibits
  • Registration
    Now Closed

  • Access the
    Recordings

Get Tickets!

PROGRAM (FEBRUARY 17 – 20)

  • Program (February 17 – 20)
  • Highlights Europe & Asia
    (March 3 & 4)
  • Industry & Satellite Symposia

Tweets by IASLC

View the Full Program at a Glance as a PDF

Times below are displayed in accordance with Eastern Standard Time (EST).

Program (February 17 – 20)
Posters
Industry & Satellite Symposia

Day 1: February 17

15:45 - 16:45 EST Early Career/ Young Investigator Session (*Sign up required)
Chair: Roy Herbst, USA
  • Academic Opportunities - Suresh Ramalingam, USA
  • Options in Industry - Leora Horn, USA
  • FDA and Regulatory Opportunities - Harpreet Singh, USA
  • Private Practice Opportunities - Edward Kim, USA
  • Basic Science Opportunities - John Minna, USA
  • Cancer Therapy Evaluation Program Externship Fellow Program, NCI - Shakun Malik, USA
  • Live Panel Discussion - Lecia Sequist, USA, Peter Ujhazy, USA, Luis Raez, USA, Paul Bunn, USA, Neal Ready, USA, Frances Shepherd, Canada

*Sign-up is required for this session by Monday, February 15 (19:00 EST) via re-accessing your registration. Instructions to sign up for the session will be emailed to you by Wednesday, February 10. Please contact [email protected] with the registration invoice attached if you did not receive the instructions. 

17:00 - 18:00 EST Welcome & Opening Keynote
  • Opening Remarks
  • Cell Free DNA - Max Diehn, USA
  • Live Panel Discussion, Paul Bunn, USA
18:10 - 19:10 EST Industry Symposium

Day 2: February 18

13:30 - 14:30 EST Targeted Therapies - EGFR
Chair: Julia Rotow, USA
  • EGFR Combinations (MET, Chemo, VEGF, Small Cell) - Helena Yu, USA
  • EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase - Collin Blakely, USA
  • EGFR Exon 20 Insetions: Novel TKIs, Amivantamab and Other Treatment Options - Zofia Piotrowska, USA
  • Persister Biology - Christine Lovly, USA
  • Live Panel Discussion - Natasha Leighl, Canada, Brian Henick, USA, Dara Aisner, USA, Jacqulyne Robichaux, USA, Hatim Husain, USA, Trever Bivona, USA, Balazs Halmos, USA, Heather Wakelee, USA
14:40 - 15:40 EST Targeted Therapies - ALK & ROS1 Inhibitors
Chair: Viola Zhu, USA
  • New Studies of Approved Agents: Crizotinib, Ceritinib, Alectinib, Lorlatinib, Ensartinib - New Data and Resistance Mechanisms - Ignatius (Sai-Hong) Ou, USA
  • New Agents Not Yet Approved: Repotectinib, DS6051b - Jessica Lin, USA
  • Combinations: VEGF, Trametinib, CDK4/6, mTOR - Shirish Gadgeel, USA
  • Continuing TKI Beyond Progression (All Drivers) - Ross Camidge, USA
  • Live Panel Discussion - Thomas Stinchcombe, USA, Elaine Shum, USA, Mark Awad, USA, Tejas Patil, USA, Greg Otterson, USA, Sandip Patel, USA, Vincent Lam, USA, Deborah Doroshow, USA
15:50 - 16:50 EST Targeted Therapies - KRAS
Chair: Sukhmani Padda, USA
  • Sotorasib for KRAS G12C - Bob Li, USA
  • Adagrasib (MRTX849) - Lyudmila Bazhenova, USA
  • Effect of Co-Mutations - John Heymach, USA
  • KRAS G12C Inhibitor Combinations - Gregory Riely, USA
  • Live Panel Discussion - David Spigel, USA, Wade Iams, USA, Michael Cheng, USA, Sarah Goldberg, USA, Vamsidhar Velcheti, USA, Adrian Sacher, Canada, Ferdinandos Skoulidis, USA, Rajwanth Veluswamy, USA
17:00 - 18:00 EST Targeted Therapies - All the Others
Chair: Misako Nagasaka, USA
  • MET - Rebecca Heist, USA
  • RET Fusion-Positive Lung Cancers - Alex Drilon, USA
  • BRAF - Ibiayi Dagogo-Jack, USA
  • HER2, NTRK, NRG1 "Too Many Topics for a Pun" - Stephen Liu, USA
  • Live Panel Discussion, Karen Kelly, USA, Xiuning Le, USA, Matthew Gubens, USA, Fadlo Khuri, Lebanon, Jonathan Riess, USA, Hirva Mamdani, USA, Erin Larkins, USA, Paul Paik, USA
18:10 - 19:10 EST Industry Symposium

Day 3: February 19

13:30 - 14:30 EST Immunotherapy - IO and other Novel Combinations
Chair: Tina Cascone, USA
  • Immunotherapy + Multi-kinase Inhibitors - Joel Neal, USA
  • Immunotherapy Combos: LAG-3, TIM-3, TIGIT, OX-40 - Rachel Sanborn, USA
  • IO + PARPi, VEGFi - Melissa Johnson, USA
  • Immunotherapy Combinations CTLA-4, 41BB, ICOS - Jarushka Naidoo, Ireland
  • Live Panel Discussion - Julie Brahmer, USA, Karen Reckamp, USA, Joshua Bauml, USA, John Wrangle, USA, Rosalyn Juergens, Canada, James Welsh, USA, Shadia Jalal, USA Parneet Cheema, Canada
14:40 - 15:40 EST Immunotherapy - Biomarkers
Chair: Natalie Vokes, USA
  • TMB and Neoantigens - Matthew Hellmann, USA
  • Statistical Models - Yu Shyr, USA
  • Multiplexed Tissue Analysis and Tumor Immune Microenvironment - Kurt Schalper, USA
  • Liquid Biopsy Approaches for Precision Immuno-Oncology - Valsamo Anagnastou, USA
  • Live Panel Discussion - Edward Garon, USA, Christian Rolfo, USA, Diane Tseng, USA, Dwight Owen, USA, Estelamari Rodriguez, USA, Katerina Politi, USA, David Kozono, USA, Aaron Mansfield, USA
15:50 - 16:50 EST Immunotherapy - Other Immunologic
Chair: Aaron Lisberg, USA
  • Personalized Cancer Vaccines - Justin Gainor, USA
  • Cellular Therapies, Adoptive T-cells - Benjamin Creelan, USA
  • Intratumoral Injections/TILs - Scott Gettinger, USA
  • Aiming the Immune System at Mutation-driven Tumors - Charu Aggarwal, USA
  • Live Panel Discussion - Naiyer Rizvi, USA, Kristen Marrone, USA, Kathryn Arbour, USA, Nasser Hanna, USA, Aparna Hegde, USA, Erin Schenk, USA, Kai He, USA, Joshua Reuss, USA
17:00 - 18:00 EST Antibody Drug Conjugates
Chair: Jose Pacheco, USA
  • Pharmacology and Toxicity of Antibody Drug Conjugates - Alex Adjei, USA
  • Antibody Drug Conjugates for HER2 and HER3 - Pasi Janne, USA
  • Trop2 ADCs: IMMU132 & DS-1062 - Ben Levy, USA
  • Other ADCs - Martin Edelman, USA
  • Live Panel Discussion - Hossein Borghaei, USA, Jacob Sands, USA, David Gerber, USA, Conor Steuer, USA, Jennifer Carlisle, USA, Jared Weiss, USA, Liza Villaruz, USA, Ryan Gentzler, USA

Day 4: February 20

09:00 - 10:00 EST Small Cell Lung Cancer
Chair: Christine Hann, USA
  • Chemo-IO in ES-SCLC - Ticiana Leal, USA
  • SCLC: Emerging Agents (Lurbinectedin, Lipo Irinotecan, APG-1252 [Pelcitoclax]) - Gregory Kalemkerian, USA
  • Emerging Immunotherapy Approaches (AMG 757, GD-2 CAR & others) - Taofeek Owonikoko, USA
  • New Therapeutic Targets for SCLC - Charles Rudin, USA
  • Radiotherapy Issues in SCLC - Kristin Higgins, USA
  • Live Panel Discussion - Anne Chiang, USA, Victoria Lai, USA, Lauren Byers, USA, Puneeth Iyengar, USA, Benjamin Drapkin, USA, Anne Tsao, USA, Afshin Dowlati, USA, Jonathan Lehman, USA
10:10 - 11:10 EST Best Fellows Oral Talk
Chair: Corey Langer, USA
  • Neratinib Efficacy in Patients with EGFR Exon 18-Mutant Non-Small Cell Lung Cancer (NSCLC): Findings from the SUMMIT Basket Trial - Amy Cummings, USA
  • Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer - Triparna Sen, USA
  • Beyond Steroids Immunosuppressants in Steroid-refractory Immune Related Adverse Events - Jia Luo, USA
  • Identifying B7-H6 as a Prospective Immunotherapy Target in Small Cell Lung Cancer - Portia Thomas, USA
  • Discussant - Ravi Salgia, USA
  • Live Panel Discussion - All Speakers
11:20 - 12:20 EST Stage III/Unresectable
Chair: Narjust Duma, USA
  • PACIFIC Trials - Jhanelle Gray, USA
  • Stage III Inoperable NSCLC: Other IO Agents - Christine Bestvina, USA
  • Ongoing Key Stage III Lung Cancer Trials in the NCTN and Beyond - Nathan Pennell, USA
  • New Innovations in Radiation Therapy for Lung Cancer - Jeffrey Bradley, USA
  • Live Panel Discussion - Andrea Bezjak, Canada, Henry Park, USA, Jonathan Spicer, Canada, Antoinette Wozniak, USA, Jyoti Patel, USA, Penelope Bradbury, Canada, Angel Qin, USA, Max Diehn, USA
12:30 - 13:30 EST Therapy for Early Stage
Chair: Sonam Puri, USA
  • Neoadjuvant Immunotherapy and Chemotherapy Plus Immunotherapy with Adjuvant Immunotherapy: Phase 2 Results and Ongoing Trials - Patrick Forde, USA
  • Adjuvant Immunotherapy and Chemo-Immunotherapy: Phase 2 Results and Ongoing Trials - Greg Durm, USA
  • Neoadjuvant and Adjuvant TKI Trials - Jamie Chaft, USA
  • Pathologic Response Evaluation - Sanja Dacic, USA
  • Live Panel Discussion - Neal Ready, USA, Jay Lee, USA, Hina Saeed, USA, Jessica Donington, USA, Brendon Stiles, USA, Catherine Shu, USA, Ray Osarogiagbon, USA, Thomas Marron, USA
13:30 - 14:00 EST Closing - Faculty Keynote
Chair: Lecia Sequist, USA
  • Academic Publishing: Now and into the Future - Alex Adjei, USA
  • Live Panel Discussion - Lecia Sequist, USA

Antibody Drug Conjugates

  • Female Lung Cancer: An Emerging Issue in Bangladesh - Muhammad Islam, Bangladesh

Immunotherapy - Biomarkers

  • Increase in Tumour PD-L1 Expression in Non-small Cell Lung Cancer Following Thermal Vapour Ablation is Not Related to Systemic Inflammatory Response - Kanishka Rangamuwa, Australia

Immunotherapy - IO and Other Novel Combinations

  • Comparison of Tumor Mutational Burden in Paired Primary Versus Lung Cancer Brain Metastasis - Matthew Strickland, USA

Immunotherapy - Other Immunologic

  • Non-Small Cell Lung Cancer (NSCLC) Comprehensive Genomic Profiling: Integrating Expanded Genomic Sequencing Into the Canadian Publicly Funded Health Care Model - Kirstin Perdrizet, Canada

Small Cell Lung Cancer

  • Detection of DNA Replication Blocker SLFN11 in Tumor Tissue and Circulating Tumor Cells to Predict Platinum Response in Small Cell Lung Cancer- Bingnan Zhang, USA

Stage III/Unresectable

  • The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC - Andrew Piper-Vallillo, USA

Targeted Therapies - ALK & ROS1 Inhibitors

  • Sequencing of TKI With or Without Brain Radiotherapy (RT) in EGFR Mutated or ALK Rearranged Non-small Cell Lung Cancer (NSCLC) with Brain Metastases – Nicholas Giustini, USA
  • Management of Advanced Non-small Cell Lung Cancer Patients Harbouring ROS1 Rearrangement- Experience From a Tertiary Cancer Centre in Eastern India – Saheli Saha, India

Targeted Therapies - All The Others

  • Precision Targeted Therapy for RET-driven NSCLC and Emerging Evidence of Acquired Resistance to RET-Specific Tyrosine Kinase Inhibitors – Johnathan Ebben, USA

Targeted Therapies - EGFR

  • Response to Standard Therapies and Comprehensive Genomic Analysis for Patients With Lung Adenocarcinoma With EGFR Exon 20 Insertions – Noura Choudhury, USA
  • Mutated EGFR Pulmonary Adenocarcinoma Experience of the Medical Oncology Department of the Hassan II Hospital University in Fez – Yassine El Ouai, Morocco
  • Mechanism of Growth-Inhibitory Effect of Pemetrexed Disodium Heptahydrate on Human PC9 (EGFR Exon 19 Deletion) Cells – Md Mohiuddin, Japan
  • Overall Survival Benefit of Osimertinib and Upfront Cranial Local Therapy in Untreated EGFR-mutant Non-small Cell Lung Cancer With Brain Metastasis – Jianjiao Ni, China
  • EGFR-TKIs Associated Cardiotoxicity in Lung Cancer Patients: An Analysis of FAERS Database – Dongchen Sun, China
  • Restoring Therapeutic Efficacy of Osimertinib in EGFR-driven NSCLC by Targeting the BMP/Endoglin Signaling Axis – Manish Thiruvalluvan, USA

Targeted Therapies - KRAS

  • The Frequency of KRAS Mutations in Brazilian Lung Cancer Patients – Rodrigo De Oliveira Cavagna, Brazil
  • Inhibitory Effect of Pemetrexed Disodium Heptahydrate on the Growth of KRAS-Dependent A549 Lung Cancer Cells – Md Mohiuddin, Japan

Therapy for Early Stage

  • Correlation Between Histological Subtypes and Prognosis in Patients with Early Stage Lung Adenocarcinoma: An Observational Retrospective Cohort Study – Stylianos Gaitanakis, Greece
  • Expressions of Biomarkers of Malignant Pleural Mesothelioma at Pham Ngoc Thach Hospital, Vietnam in 5 Years From 2015-2019 – Nguyen Lam, Viet Nam

 

Please click here to view the Industry & Satellite Symposia sessions.

Click here for information about the Europe & Asia international sessions on March 3 & 4.

February 17
February 18
February 19
February 20
15:45 - 16:45 EST Early Career/ Young Investigator Session (by invitation only)
View Presentations
  • Academic Opportunities – Suresh Ramalingam, USA
  • Industry Opportunities – Leora Horn, USA
  • FDA and Regulatory Opportunities – Harpreet Singh, USA
  • Private Practice Opportunities – Edward Kim, USA
  • Basic Science Opportunities – John Minna, USA
  • Cancer Therapy Evaluation Program (CTEP) Externship Fellow Program, NCI – Shakun Malik, USA

17:00 - 18:00 EST Welcome & Opening Keynote
View Presentations
  • Opening Remarks
  • Cell Free DNA – Max Diehn, USA
  • Live Panel Discussion

18:10 - 19:10 EST Industry Symposium

 

13:30 - 14:30 EST Targeted Therapies EGFR
View Presentations
  • EGFR + MET, EGFR + Chemo, EGFR + VEGF, SCLC
  • Other EGFR Combo’s:  MEK, Aurora K, C797S
  • Exon 20 and Amivantimab
  • Persister Biology Talk (All Drivers)
14:40 - 15:40 EST Targeted Therapies ALK & ROS
View Presentations
  • New Studies of Approved Agents: Crizotinib, Ceritinib, Alectinib, Lorlatinib, Ensartinib – New Data and Resistance Mechanisms; Brigatinib
  • New Agents Not Yet Approved: Repotectinib, DS6051b, TPX-0131
  • Combinations: VEGF, Trametinib, CDK4/6, mTOR
  • Continuing TKI Beyond Progression (All Drivers- RET, MET, EGFR, etc.)
15:50 - 16:50 EST Targeted Therapies KRAS
View Presentations
  • Sotorasib
  • Mirati – (Adagrasib?)
  • Effect of Co-Mutations
  • Combinations
17:00 - 18:00 EST Targeted Therapies All the Others
View Presentations
  • MET
  • RET
  • BRAF
  • HER2, NRG Fusions, NTRK
18:10 - 19:10 EST Industry Symposium
13:30 - 14:30 EST Immunotherapy
14:40 - 15:40 EST IO Biomarkers 
View Presentations
  • TMB and Other Neoantigen Quanitification Methods
  • Statistical Models
  • Multi-fluorescence, TME
  • Blood Based Biomarkers
15:50 - 16:50 EST IO Other Immunologic
View Presentations
  • Personalized Cancer Vaccines
  • Cellular Therapies, Adoptive T-cells
  • Intratumoral Injections, TILs
  • Aiming the Immune System at Mutation-driven Tumors
17:00 - 18:00 EST Antibody Drug Conjugates
View Presentations
  • Pharmacology, Toxicity
  • ADC for HER 2, HER3 incl Trastuzimab Ematansine and Dexretuxin, DS8021, U31402
  • ADC for Trop 2 incl DS1062, Immuno 132
  • Other ADCs
18:10 - 19:10 EST Industry Symposium
09:00 - 10:00 EST SCLC 
View Presentations
  • Chemotherapy + IO
  • Emerging Novel Agents (Lurbinectedin, PARPi, Irinotecan Liposome, APG-1252)
  • Emerging Immunotherapy Approaches (AMG 757, GD-2 CAR & others)
  • New Therapeutic Targets for SCLC
  • Radiotherapy Issues in SCLC
10:10 - 11:10 EST Best Fellows Oral Talk
11:20 - 12:20 EST Stage III Unresectable 
View Presentations
  • PACIFIC Trials
  • Other IO Agents (Besides Durvalumab) & Combinations
  • Ongoing Key Stage III Trials in the NCTN and Beyond
  • Innovations in Radiotherapy
  • Nasser Hanna as backup if Dr. Bezjak is not available
12:30 - 13:30 EST Therapy for Early Stage 
View Presentations
  • Neoadjuvant Immunotherapy and Chemotherapy Plus Immunotherapy with Adjuvant Immunotherapy: Phase 2 Results Including Safety and Ongoing Trial Design
  • Adjuvant Immunotherapy and Chemo-Immunotherapy: Phase 2 Results and Ongoing Trials
  • Neoadjuvant and Adjuvant TKI Therapy Trials Results, NGS Testing and Safety
  • Pathologic Response Evaluation
13:30 - 14:00 EST Closing - Faculty Keynote


  • Stay Connected

    Keep up to date with the latest news & alerts.
    Sign Up


     
    #TTLC21
© 2021 International Association for the Study of Lung Cancer – IASLC TTLC 2021 | Privacy Notice

Conference Newsletter
Subscribe to the Newsletter to receive important information about the upcoming Meeting.
Thank you! We look forward to connecting soon.
Click here to close this window
Whoops, looks like there was an issue with one of the fields above - please review above.
X